Skip to main content

Cerus Corporation

corporate_fare Company Profile

Cerus Corporation

CERS·NASDAQ·Industrial Applications And Services·CIK 0001020214

CERUS CORP is a biomedical products company that develops and commercializes the INTERCEPT Blood System to enhance blood safety. This system uses proprietary technology to control biological replication, aiming to reduce blood-borne pathogens in donated blood components for transfusion. The INTERCEPT Blood System is designed for use with platelets, plasma, red blood cells, and to produce INTERCEPT Fibrinogen Complex (IFC) and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for platelets (platelet system) and the INTERCEPT Blood System for plasma (plasma system) have received various regulatory approvals and certifications. These include FDA approval in the U.S. and CE Certificates of Conformity under Medical Devices Regulation 2017/745, allowing the CE Mark for sale in the European Union and other recognizing jurisdictions. These systems are marketed and sold globally, including in the U.S., parts of Europe, the Commonwealth of Independent States (CIS), the Middle East, Latin America, and selected countries in other regions. CERUS CORP also has FDA approval for the INTERCEPT Blood System for Cryoprecipitation. This system utilizes the plasma system to produce IFC for treating and controlling bleeding, including massive hemorrhage, associated with fibrinogen deficiency. It also produces pathogen reduced plasma, cryoprecipitate reduced. The company sells its platelet and plasma systems through a direct sales force and distributors. IFC or disposable kits for manufacturing IFC are sold in the U.S. via a direct sales force.

Cerus Corporation (NASDAQ:CERS) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 18 items for CERS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-02, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 8/10, with 9 rated 8 or above. Recent SEC coverage for CERS spans 10-Q, 8-K, DEFA14A, DEF 14A.

Recent high-impact activity:

  • Q3 Product Revenue Up 10% to $57.7M, Net Loss Narrows to $0.6M
  • Phase 3 RedeS Hits Primary Endpoint, Paving Path for INTERCEPT Red Blood Cells
  • Cerus lifts full-year outlook as Q2 revenue climbs 10% and losses narrow
  • Cerus Q2 Revenue Beats, Raises 2026 Guidance on Strong IFC Demand
  • Cerus Secures Up To $110M New Debt Facility to Boost Liquidity and Refinance Existing Loans

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$233.8M
Net Income
-$15.63M
Diluted EPS
-$0.08
Op. Cash Flow
$4.84M
Free Cash Flow
$1.11M
Operating Income
-$8.68M
Cash & Equivalents
$19.96M
Debt / Equity
0.00×
Net Margin
-6.7%
Shares Outstanding
192.14M sh
Source: 10-K · filed 2026-03-02 · accession 0001193125-26-085678

Short Interest & Short Volume

8.18 days to cover

FINRA reported short interest of 14,631,896 shares in CERS as of the October 30, 2026 settlement, a 12.0% decrease from the prior period — about 8.2 days to cover at its recent average daily volume. On November 20, 2026, 63.2% of CERS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)14,631,896 shares as of October 30, 2026
Change vs prior period▼ 12.0%
Days to cover8.18 at avg daily volume of 1,789,321
Daily short volume (FINRA facilities)63.2% of 1,204,930 shares on November 20, 2026
5-day average short volume67.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for CERS, detected from its recent SEC filings · based on capital-structure filings through 2026-11-02.

1 shelf registration

Universal Shelf Registered · Carried Forward, No New Fee

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with C →
$1.83 -1.08% today
52-week range · as of 2026-07-30 $1.15 – $3.47
Market cap
$373.62M
Volume
4.5M (1.7× avg)
3-mo avg 2.7M
Live data · 2026-11-22 07:58 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CERS - Latest Insights

CERS
Nov 02, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $2.66
Real-time Price: $1.83 info
Change: -$0.830 (-31%) info
Market Cap: $373.615M info
CERS
Nov 02, 2026, 4:00 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $2.35
Real-time Price: $1.83 info
Change: -$0.520 (-22%) info
Market Cap: $373.615M info
CERS
Jul 30, 2026, 4:44 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.50
Real-time Price: $1.83 info
Change: -$0.670 (-27%) info
Market Cap: $373.615M info
CERS
Jul 30, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.55
Real-time Price: $1.83 info
Change: -$0.720 (-28%) info
Market Cap: $373.615M info
CERS
Jun 08, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.60
Real-time Price: $1.83 info
Change: -$0.770 (-30%) info
Market Cap: $373.615M info
CERS
Jun 08, 2026, 8:42 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $2.71
Real-time Price: $1.83 info
Change: -$0.880 (-32%) info
Market Cap: $373.615M info
CERS
Jun 03, 2026, 4:17 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.66
Real-time Price: $1.83 info
Change: -$0.830 (-31%) info
Market Cap: $373.615M info
CERS
May 27, 2026, 12:52 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $2.82
Real-time Price: $1.83 info
Change: -$0.990 (-35%) info
Market Cap: $373.615M info
CERS
Apr 30, 2026, 5:05 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $2.16
Real-time Price: $1.83 info
Change: -$0.330 (-15%) info
Market Cap: $373.615M info
CERS
Apr 30, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.25
Real-time Price: $1.83 info
Change: -$0.420 (-19%) info
Market Cap: $373.615M info
CERS
Apr 22, 2026, 12:01 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $1.95
Real-time Price: $1.83 info
Change: -$0.115 (-6%) info
Market Cap: $373.615M info
CERS
Apr 22, 2026, 12:00 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $1.95
Real-time Price: $1.83 info
Change: -$0.115 (-6%) info
Market Cap: $373.615M info
CERS
Apr 21, 2026, 4:21 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.92
Real-time Price: $1.83 info
Change: -$0.090 (-5%) info
Market Cap: $373.615M info
CERS
Mar 16, 2026, 5:18 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.80
Real-time Price: $1.83 info
Change: +$0.030 (+2%) info
Market Cap: $373.615M info
CERS
Mar 02, 2026, 5:03 PM EST
Filing Type: 10-K
Importance Score:
7
Price at Filing: $2.50
Real-time Price: $1.83 info
Change: -$0.670 (-27%) info
Market Cap: $373.615M info
CERS
Mar 02, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.53
Real-time Price: $1.83 info
Change: -$0.700 (-28%) info
Market Cap: $373.615M info
CERS
Mar 02, 2026, 4:01 PM EST
Source: Reuters
Importance Score:
8
Price at Filing: $2.52
Real-time Price: $1.83 info
Change: -$0.690 (-27%) info
Market Cap: $373.615M info
CERS
Jan 12, 2026, 8:06 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.06
Real-time Price: $1.83 info
Change: -$0.230 (-11%) info
Market Cap: $373.615M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets